Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yechun Xu

Showing results (131-140 of 154) with videos related to

Pageof 16
Sort By:
Journal of Medicinal Chemistry|December 12, 2025
Correction to "Kinetics-Driven Drug Design Strategy for Next-Generation Acetylcholinesterase Inhibitors to Clinical Candidate"Yu Zhou, Yan Fu, Wanchao Yin, et al.
Journal of Medicinal Chemistry|November 10, 2012
Design, synthesis, and pharmacological evaluation of monocyclic pyrimidinones as novel inhibitors of PDE5Guan Wang, Zheng Liu, Tiantian Chen, et al.
Journal of Medicinal Chemistry|February 11, 2021
Kinetics-Driven Drug Design Strategy for Next-Generation Acetylcholinesterase Inhibitors to Clinical CandidateYu Zhou, Yan Fu, Wanchao Yin, et al.
Nature Communications|June 3, 2024
PPIA dictates NRF2 stability to promote lung cancer progressionWeiqiang Lu, Jiayan Cui, Wanyan Wang, et al.
European Journal of Medicinal Chemistry|October 15, 2014
Discovery of potent N-(isoxazol-5-yl)amides as HSP90 inhibitorsDanqi Chen, Aijun Shen, Jian Li, et al.
Nature Communications|December 15, 2025
Author Correction: PPIA dictates NRF2 stability to promote lung cancer progressionWeiqiang Lu, Jiayan Cui, Wanyan Wang, et al.
Acta Pharmaceutica Sinica. B|January 23, 2024
Structure-based development of potent and selective type-II kinase inhibitors of RIPK1Ying Qin, Dekang Li, Chunting Qi, et al.
Nature Communications|June 16, 2021
Identification of pyrogallol as a warhead in design of covalent inhibitors for the SARS-CoV-2 3CL proteaseHaixia Su, Sheng Yao, Wenfeng Zhao, et al.
Journal of Medicinal Chemistry|January 7, 2015
Fragment-based drug discovery of 2-thiazolidinones as BRD4 inhibitors: 2. Structure-based optimizationLele Zhao, Yingqing Wang, Danyan Cao, et al.
Journal of Medicinal Chemistry|July 24, 2019
Discovery and Development of a Series of Pyrazolo[3,4-<i>d</i>]pyridazinone Compounds as the Novel Covalent Fibroblast Growth Factor Receptor Inhibitors by the Rational Drug DesignYulan Wang, Yang Dai, Xiaowei Wu, et al.
Pageof 16

Showing results (131-140 of 154) with videos related to

Sort By:
Pageof 16
Journal of Medicinal Chemistry|December 12, 2025
Correction to "Kinetics-Driven Drug Design Strategy for Next-Generation Acetylcholinesterase Inhibitors to Clinical Candidate"Yu Zhou, Yan Fu, Wanchao Yin, et al.
Journal of Medicinal Chemistry|November 10, 2012
Design, synthesis, and pharmacological evaluation of monocyclic pyrimidinones as novel inhibitors of PDE5Guan Wang, Zheng Liu, Tiantian Chen, et al.
Journal of Medicinal Chemistry|February 11, 2021
Kinetics-Driven Drug Design Strategy for Next-Generation Acetylcholinesterase Inhibitors to Clinical CandidateYu Zhou, Yan Fu, Wanchao Yin, et al.
Nature Communications|June 3, 2024
PPIA dictates NRF2 stability to promote lung cancer progressionWeiqiang Lu, Jiayan Cui, Wanyan Wang, et al.
European Journal of Medicinal Chemistry|October 15, 2014
Discovery of potent N-(isoxazol-5-yl)amides as HSP90 inhibitorsDanqi Chen, Aijun Shen, Jian Li, et al.
Nature Communications|December 15, 2025
Author Correction: PPIA dictates NRF2 stability to promote lung cancer progressionWeiqiang Lu, Jiayan Cui, Wanyan Wang, et al.
Acta Pharmaceutica Sinica. B|January 23, 2024
Structure-based development of potent and selective type-II kinase inhibitors of RIPK1Ying Qin, Dekang Li, Chunting Qi, et al.
Nature Communications|June 16, 2021
Identification of pyrogallol as a warhead in design of covalent inhibitors for the SARS-CoV-2 3CL proteaseHaixia Su, Sheng Yao, Wenfeng Zhao, et al.
Journal of Medicinal Chemistry|January 7, 2015
Fragment-based drug discovery of 2-thiazolidinones as BRD4 inhibitors: 2. Structure-based optimizationLele Zhao, Yingqing Wang, Danyan Cao, et al.
Journal of Medicinal Chemistry|July 24, 2019
Discovery and Development of a Series of Pyrazolo[3,4-<i>d</i>]pyridazinone Compounds as the Novel Covalent Fibroblast Growth Factor Receptor Inhibitors by the Rational Drug DesignYulan Wang, Yang Dai, Xiaowei Wu, et al.
Pageof 16